A Phase 2/3 interventional study of Autologous PRP intra ovarian infusion and Autologous PFP intra ovarian infusion in Infertility, Female, Anovulatory Infertility and Menopause, sponsored by Genesis Athens Clinic. Recruiting at 1 site in Greece. Open to female participants aged 45 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Genesis Athens Clinic · Phase 2/3, Interventional, and Treatment
Autologous PRP intra ovarian infusion may restore ovarian function, may promote folliculogenesis and may improve hormonal profile of women in menopause.
This triple-blind Randomized Controlled Trial (RCT) aims to investigate the effectiveness of autologous PRP intra ovarian infusion on reactivating ovarian functionality and on promoting folliculogenesis in regard to menopausal women. PRP is blood plasma prepared from fresh whole blood that has been enriched with platelets. It is collected from peripheral veins and contains several growth factors such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor (TGF) and other cytokines all of which stimulate tissue proliferation and growth. PRP has been employed in several medical conditions in Orthopedics, Dermatology, and Ophthalmology for wound healing. It's efficacy in ovarian rejuvenation and reactivation and endometrial regeneration has not been fully elucidated. This study aims to investigate the effect of autologous PRP intra ovarian infusion on restoring ovarian tissue functionality in menopausal women.
Exclusion Criteria:
Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.
Biological: Autologous PRP intra ovarian infusion
Women in menopause, 45-55 years old, treated with autologous PFP intra ovarian infusion.
Biological: Autologous PFP intra ovarian infusion
Autologous PRP intra ovarian infusion
Autologous PFP intra ovarian infusion
Restoration of menstrual cycle
Menstrual cycle restoration
Time frame: Three months
Serum FSH levels
Serum FSH levels evaluated monthly for three consecutive months.
Time frame: Follow-up period of three months entailing monthly evaluation
Serum AMH levels
Serum AMH levels evaluated monthly for three consecutive months.
Time frame: Follow-up period of three months entailing monthly evaluation
Serum estradiol levels
Serum estradiol levels evaluated monthly for three consecutive months.
Time frame: Follow-up period of three months entailing monthly evaluation
Serum LH levels
Serum LH levels evaluated monthly for three consecutive months.
Time frame: Follow-up period of three months entailing monthly evaluation
Serum progesterone levels
Serum progesterone levels evaluated monthly for three consecutive months.
Time frame: Follow-up period of three months entailing monthly evaluation
Antral Follicle Count
AFC evaluated monthly, on day 2 of the menstrual cycle, for three consecutive months.
Time frame: Follow-up period of three months entailing monthly evaluation
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genesis Athens Clinic